Why brokers give the Ramsay Health (ASX:RHC) share price a thumbs up

Although the Ramsay share price has been volatile of late, brokers seem to see plenty of upside. Here's why.

| More on:
positive asx share price represented by lots of hands all making thumbs up gesture

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Ramsay Health Care Limited (ASX: RHC) share price has been on a rollercoaster ride recently.

Shares in the health care company reached a high of $69.49 in November only to fall as low as $58.71 in January. At the time of writing, the Ramsay Health share is trading at $63.66, up 2.22%.

Despite the volatility, it appears that brokers are positive about the future of the company. We take a look at some of the reasons why. 

A major acquisition

Ramsay Health Care announced last month that it was putting a cash offer to acquire the UK-based Spire Group. Spire is an independent hospital group focused on the private patient market and a leading provider of high-acuity care.

The UK acquisition appears to be a logical step for Australia's largest private hospital provider.

As described in its company literature, Ramsay "provides quality health care through a global network of clinical practice, teaching and research". The company says its global network extends across 10 countries, with more than eight million admissions/patient visits to its facilities in more than 460 locations.

Which brokers are positive on the company?

Citi Bank yesterday upgraded Ramsay Health Care to a buy.  The broker attributed to rating upgrade to the recent fall in the Ramsay share price and the fact that company has underperformed the ASX 200 by 14% in the last quarter. 

Citi expects an big upside with the Spire acquisition, COVID-19 restrictions being lifted and hospitals getting back to normal.

Analysts at Macquarie are also positive about the healthcare company.  Macquarie has retained its outperform rating and $74.85 price target on Ramsay Health Care.

Macquarie believes that the Spire deal stems well for the Ramsay share price and long term growth in the lucrative UK market.

With the Ramsay share price currently trading around $63, Macquarie's price target is a whopping 20% upgrade on the current price.

.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This biotech company's shares are on a tear – again – after another contract win

A new contract with a prestigious US institution spells good news for shareholders.

Read more »

Child with superhero mask and cape flies after jumping on sofa
AI Stocks

3 of the fastest-growing stocks on the planet in 2025

These stocks soared in 2025.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Could CSL shares outperform the ASX 200 in 2026?

After shocking investors in 2025, CSL shares may be setting up for a comeback. Here’s why 2026 could look better.

Read more »

A man holds his head in his hands after seeing bad news on his laptop screen.
Healthcare Shares

Why did CSL shares crash 39% in 2025?

Should you be buying the dip? Let's find out.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Why 4DMedical shares are jumping 14% today

4DMedical shares climb on a new CFO appointment as investors focus on US expansion and rising use of its lung…

Read more »

A business woman flexes her muscles overlooking a city scape below.
Healthcare Shares

Why I plan to buy this incredible ASX 200 stock in 2026

A 33% pullback has put Pro Medicus back in focus. Here’s why I’m preparing to buy its shares in 2026.

Read more »

research with microscope
Healthcare Shares

This ASX healthcare stock just changed its debt. Here's why it matters

Shares in Mesoblast edge higher after the company announces a major change to its debt and funding structure.

Read more »

stock growth chart
Healthcare Shares

Will CSL shares crash again in 2026?

CSL shares have fallen almost 40% in 2025. Investors are now asking if the worst is already behind the stock.

Read more »